1 Title: Pan-cancer detection and typing by mining patterns in large genome-wide cell-free

- 2 **DNA** sequencing datasets
- 3

4 Running head: cfDNA data mining for cancer detection

5

Authors: Huiwen Che¹, Tatjana Jatsenko¹, Liesbeth Lenaerts², Luc Dehaspe³, Leen 6 7 Vancoillie³, Nathalie Brison³, Ilse Parijs³, Kris Van Den Bogaert³, Daniela Fischerova⁴, Ruben Heremans⁵, Chiara Landolfo⁶, Antonia Carla Testa⁷, Adriaan Vanderstichele⁶. Lore Liekens⁸. 8 Valentina Pomella⁸, Agnieszka Wozniak⁹, Christophe Dooms^{10,11}, Els Wauters^{10,11}, Sigrid 9 Hatse^{9,12,} Kevin Punie^{12,13}, Patrick Neven^{6,12}, Hans Wildiers^{12,13}, Sabine Tejpar⁸, Diether 10 11 Lambrechts¹⁴, An Coosemans¹⁵, Dirk Timmerman^{5,6}, Peter Vandenberghe^{16,17}, Frédéric 12 Amant^{2,6,18}, Joris Robert Vermeesch^{1,3*} **Affiliations:** 13 14 ¹Department of Human Genetics, Laboratory for Cytogenetics and Genome Research, KU 15 Leuven, Leuven, Belgium. 16 ²Department of Oncology, Laboratory of Gynecological Oncology, KU Leuven, Leuven, 17 Belgium. ³Centre for Human Genetics, University Hospitals Leuven, Leuven, Belgium. 18 19 ⁴Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University and 20 General University Hospital in Prague, Prague, Czech Republic. 21 ⁵Department of Development and Regeneration, Woman and Child, KU Leuven, Leuven,

22 Belgium.

- 23 ⁶Department of Gynecology and Obstetrics, University Hospitals Leuven, Leuven, Belgium.
- ⁷Department of Woman and Child Health, Fondazione Policlinico Universitario A. Gemelli, 24
- 25 IRCCS, Università Cattolica del Sacro Cuore Roma, Rome, Italy. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- ⁸Department of Oncology, Molecular Digestive Oncology, KU Leuven, Leuven, Belgium.
- ⁹Department of Oncology, Laboratory of Experimental Oncology, KU Leuven, Leuven,
 Belgium.
- ¹⁰Department of Chronic Diseases and Metabolism, Laboratory of Respiratory Diseases and
- 30 Thoracic Surgery (BREATHE), KU Leuven, Leuven, Belgium.
- 31 ¹¹Department of Pneumology, University Hospitals Leuven, Leuven, Belgium.
- 32 ¹²Multidisciplinary Breast Centre, Leuven Cancer Institute, University Hospitals Leuven,
- 33 Leuven, Belgium.
- ¹³Department of General Medical Oncology, Leuven Cancer Institute, University Hospitals
- 35 Leuven, Leuven, Belgium.
- ¹⁴Department of Human Genetics, Laboratory of Translational Genetics, VIB-KU Leuven,
- 37 Leuven, Belgium.
- ¹⁵Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, Leuven
- 39 Cancer Institute, KU Leuven, Leuven, Belgium.
- 40 ¹⁶Department of Human Genetics, Laboratory of Genetics of Malignant Diseases, KU Leuven,
- 41 Leuven, Belgium.
- 42 ¹⁷Department of Hematology, University Hospitals Leuven, Leuven, Belgium.
- 43 ¹⁸Center for Gynecological Oncology Amsterdam: Academic Medical Centre Amsterdam-
- 44 University of Amsterdam and The Netherlands Cancer Institute-Antoni van Leeuwenhoek
- 45 Hospital, Amsterdam, the Netherlands.
- 46
- 47 *Corresponding author: Joris Robert Vermeesch, Katholieke Universiteit Leuven (KU Leuven)
- 48 Universitaire Ziekenhuizen Leuven (University Hospitals Leuven), Human Genetics,
- 49 Herestraat 49, box 602, 3000 Leuven, Belgium.
- 50 Telephone: +32 16 34 5941

Email: joris.vermeesch@uzleuven.be 51

52 Abstract

53 Background

54 Cell-free DNA (cfDNA) analysis holds great promise for non-invasive cancer screening,

55 diagnosis and monitoring. We hypothesized that mining the patterns of big datasets of shallow

56 whole genome sequencing cfDNA from cancer patients could improve cancer detection.

57 Methods

58 By applying unsupervised clustering and supervised machine learning on large shallow whole-

59 genome sequencing cfDNA datasets from healthy individuals (n=367), patients with different

60 hematological (n=238) and solid malignancies (n=320), we identify cfDNA signatures that

61 enable cancer detection and typing.

62 **Results**

Unsupervised clustering revealed cancer-type-specific sub-grouping. Classification using supervised machine learning model yielded an overall accuracy of 81.62% in discriminating malignant from control samples. The accuracy of disease type prediction was 85% and 70% for the hematological and solid cancers, respectively. We demonstrate the clinical utility of our approach by classifying benign from invasive and borderline adnexal masses with an AUC of 0.8656 and 0.7388, respectively.

69 Conclusions

This approach provides a generic and cost-effective strategy for non-invasive pan-cancerdetection.

72

key words: liquid biopsy, cfDNA, ctDNA, hematological malignancies, solid tumors, ovarian
tumors, machine learning

75 Introduction

Cell-free DNA (cfDNA) is a promising non-invasive biomarker in liquid biopsy for cancer management. Shallow whole-genome sequencing (sWGS) of cfDNA can identify cancerspecific copy number aberrations (CNAs) in cancer patients (1,2). Using genome-wide cfDNA sequencing data to profile genomic imbalances, we reported that CNAs in the asymptomatic population can be indicative of incipient tumors and has potential as a cancer screening tool (3).

82

83 In addition to CNAs, sequencing of cfDNA provides a unique view on the genome-wide 84 cfDNA fragmentation profile (4,5). CfDNA fragments carry tissue-associated nucleosome and 85 preferred end position information (6,7), reflecting tissue-specific degradation, chromatin 86 accessibility and nucleosome organization of its cellular origin (8,9). In healthy individuals, 87 plasma cfDNA comprises DNA fragments that are mainly resulting from apoptotic release of 88 DNA from the cells of hematopoietic origin (10). In plasma of cancer patients, circulating 89 tumor DNA (ctDNA) has decreased fragment sizes and signatures of the tissue of origin (8,11). 90 Consequently, fragmentomics is emerging as an approach to reveal cfDNA properties, 91 broadening the potential of cfDNA as a biomarker (4,12).

92

Increasing availability of cfDNA sWGS data from large-scale liquid biopsy projects offer unique opportunities to explore the cfDNA profiles by machine learning. We hypothesized that mining variation between sWGS profiles may uncover distinct patterns that can be associated with different pathological or physiological states. Hence, we applied an unsupervised clustering analysis and supervised machine learning workflow, which we term GIP*Xplore*, on a large number of genome-wide sWGS cfDNA profiles from cancer patients with different hematological and solid tumors and unveiled cancer-type-specific and also shared tumor-

- 100 associated signatures that are absent in healthy individuals. This approach enables accurate
- 101 detection of different cancers and allows prediction of the cancer types.

102 Materials and Methods

103 **Patients and clinical data**

The study was approved by the ethical committee of the University Hospitals Leuven (S57999, S62285, S62795, S50623, S56534, S63240, S51375, S59207, S64205 and S64035). Samples and consents were obtained from healthy controls and cancer patients. Blood was collected either into Streck Cell-Free DNA BCT or Roche Cell-Free DNA Collection Tubes. Plasma was isolated via a standard, two-step centrifugation procedure and stored at -80°C. Previously published sequencing data from 260 healthy subjects (3) and 177 patients with Hodgkin's lymphoma (13) were included in the study.

111

112 sWGS Analysis

113 cfDNA was extracted from plasma using standard processing procedures and sWGS sequencing (14) (details described in the Supplemental Materials). Each sample ended with 114 115 57509 autosome bin features from standard processing. Principal component analysis (PCA) 116 was used for dimension reduction to transform data from high dimension to low dimension. 117 We performed the supervised learning on both the original data space and PCA transformed 118 space and found marginal gains of performance in the majority of analyses with the original 119 data space. As the computational time was much higher using the original data space, we used 120 PCA features in the main analyses such that features being used in both unsupervised and 121 supervised learning were consistent.

122

123 GIPXplore

As illustrated in **Fig. 1**, we developed GIP*Xplore* to mine sWGS cfDNA data for identification of signatures. We utilized unsupervised clustering and supervised machine learning. For unsupervised clustering, we evaluated the variance being explained from principal components

127 (PCs) in the tumor data. Overall, the top 30, 50 and 100 PCs explained above 80%, 85% and 128 90% of the variance in the data, respectively. While there is no absolute optimal number of 129 PCs to be used for further analysis, non-trivial components - 50 PCs (Supplemental 130 Materials) were determined as a default number for downstream analyses in the results. The 131 Euclidean metric was used to measure dissimilarity among samples for clustering analysis. 132 Proximity matrix based on dissimilarity of samples was generated. The t-distributed stochastic 133 neighbor embedding (tSNE) (15) was used to map high-dimensional data to two (or three) 134 dimensions and to visualize the clusters. Due to the random process of tSNE, we applied 135 Walktrap community (16) detection on the original proximity matrix for cluster assignments 136 regardless of the presentation of tSNE visualization. In running tSNE, we set parameters 137 perplexity of 15/30 and iteration of 10000 with exact tSNE for accuracy, and the process was 138 repeated for 10 times with different seeds. For Walktrap, we used the parameters of 8 initial numbers of neighbors search and a walk step of 2. Clusters defined from the community 139 140 detection were used for annotation. In supervised learning, PCA transformed genome-wide 141 features were used in the machine learning model for training. PCA was performed on training 142 data, and test data was projected on PCA space of training data for classification tasks. We 143 measured performance by repeating the tenfold cross-validation 10 times and leave-one-out 144 (LOO) procedures. For cross fold (CV) validation, the ROC curve and performance was 145 calculated by averaging over 10 repeats. For classifiers, we used a support vector machine 146 (SVM) and hyperparameters were chosen based on the grid search with a subset of the data. A 147 separate model was trained to localize tissue of origin and LOO was used to evaluate performance characteristics. Weighted sample size was accounted for in the model for 148 149 imbalanced classes.

All rights reserved. No reuse allowed without permission.

150 **Results**

151 GIPXplore detects and classifies hematological malignancies with high accuracy

152 To assess the potential, we applied our method on a set of cfDNA samples from healthy 153 controls (n=260) and patients with hematological malignancies that included Hodgkin's 154 lymphoma (HL; n=179), diffuse large B-cell lymphoma (DLBCL; n=37), multiple myeloma 155 (MM; n=22) (Table 1). Walktrap community detection was performed on the dataset, and 15 156 clusters were defined. Visualization with the tSNE vielded separations between malignant and 157 healthy control profiles, and the tSNE representation was largely in agreement with the clusters 158 found by Walktrap (Fig. 2, A). Moreover, we observed cancer type-specific clusters. Cluster 159 1, 3 and 4 was exclusively composed of HL samples. Cluster 9 was enriched for DLBCL 160 samples, and cluster 13 was specific to MM samples (Fig. 2, B and Supplemental Fig. 1).

161

162 In parallel, we benchmarked our method against the ichorCNA (17) algorithm for copy number 163 profiling and tumor fraction (TF) estimation from sWGS data. IchorCNA utilizes the depth of 164 coverage to evaluate the presence of large-scale copy number aberrations and the probabilistic 165 model is used to infer copy number states and estimate fraction of tumor. Overall, only 52.95% 166 of hematological cancer samples had detectable tumor-derived cfDNA levels (Fig. 2, C, 167 Supplemental Fig. 2 and Supplemental Table 1), using the 3% detection limit suggested in 168 the ichorCNA for detecting the presence of tumor. The above-mentioned clusters 1, 3, and 4 consisted of profiles characterized by large chromosomal aberrations and high tumor load. 169 170 Clusters 2 and 8 consisted of profiles from HL patients with both high and low tumor fractions, implying that the clustering was not completely CNA-driven. In particular, ten out of 65 171 172 (15.38%) lymphoma samples in cluster 2 with normal-like profiles (without detectable CNAs) grouped together with samples characterized by detectable CNAs. A less pronounced 173 174 separation could be observed between clusters containing healthy controls and cluster 8, in

175 which 76.47% (26 out of 34) malignant cases had normal-like profiles with less than 3% TFs. 176 Nine HL samples in cluster 10 showed higher bin-to-bin log2 ratio variations and were more 177 likely to be noisy on a genome-wide scale (Fig. 2, D and Supplemental Fig. 3). The remaining 178 malignant cases without detectable CNAs co-localized with healthy controls. To further 179 explore whether clustering of malignant samples would be mainly CNA-driven, we performed 180 clustering analysis using the log2 copy ratio values produced by ichorCNA. The analysis 181 revealed that genome-wide copy number ratios alone were less informative (Supplemental 182 Fig. 4). In addition, we tested whether our method could detect underlying genome-wide 183 changes irrespective of the presence of CNAs by restricting the clustering to the cancer samples 184 with low TF (< 3%). The separation between some malignant and healthy samples still 185 remained (Supplemental Fig. 5). Collectively, the clustering analysis on genome-wide 186 features showed separation between malignant and healthy profiles and grouping of similar 187 cancer type-specific profiles.

188

189 The unsupervised learning delineated cancer-associated profile changes, which suggested that 190 a more precise prediction can be made by learning representations within different tumor types 191 using supervised classification. Therefore, we evaluated the capability to detect cancer signals 192 and identify cancer types with supervised learning on the hematological cohort. Both leave-193 one-out (LOO) and repeated 10-fold cross validation (CV) was used to assess the performance 194 of the classifier. Incorporating transformed genome-wide features, the SVM machine learning 195 model correctly classified 220 (out of 238) malignant cases in LOO analysis, at a sensitivity of 196 92.44% (95% CI: 88.31% - 95.46%) and a specificity of 98.46% (95% CI: 96.11% - 99.58%), 197 including 170 HL, 32 DLBCL and 18 MM cfDNA samples (Supplemental Table 1). The 198 remaining 18 misclassified malignant samples had normal-like profiles and clustered together 199 with healthy controls (Supplemental Fig. 6). The detection sensitivity was the highest for HL

200 (Supplemental Table 1). The sensitivity did not differ substantially between early (I-II) and 201 advanced (III-IV) stages for these cancer types, though the distribution of the cases across 202 clinical stages was unequal (Fig. 3, A). ROC analysis had an AUC value of 0.989 (95% CI: 203 0.980 - 0.998) in distinguishing malignant from healthy samples, compared to ichorCNA TF-204 based analysis which had an AUC of 0.929 (Fig. 3, B). Repeated 10-fold CV also revealed a 205 stable performance at an averaged AUC of 0.989 (Supplemental Fig. 7). As the clustering 206 analysis demonstrated the co-localization of samples originating from the same cancer type, 207 we then attempted to determine the accuracy of our GIPXplore in cancer type classification. 208 For this purpose, we trained the classification model using the 220 correctly predicted 209 malignant samples. The analysis showed an overall accuracy of 85.45% (95% CI: 80.09% -210 89.83%), with the highest accuracy in HL prediction (Fig. 3, C and Supplemental Table 2). 211 Consistent with the exploratory clustering analysis, where some of the profiles from DLBCL 212 patients colocalized together with those from HL patients, DLBCL samples were more likely 213 to be misclassified.

214

GIPXplore identifies and classifies different types of solid malignancies and allows disease stratification

217 Extending our analyses, we applied our method on a solid tumor dataset, consisting of 320 218 cfDNA profiles from cancer patients, and a set of 107 cfDNA profiles from healthy controls. 219 The malignant cohort was represented by five tumor types: breast (n=46), colorectal (n=70), 220 gastrointestinal stromal tumor (GIST; n=35), lung (n=44) and ovarian (n=125; **Table 1**). Using 221 GIPXplore, 19 clusters were identified in the solid tumor dataset (Fig. 4, A and Supplemental 222 Fig. 8). The separations between malignant and control cfDNA profiles were less distinct 223 compared to clustering results of the hematological cancer dataset. Clusters 4, 8, 10 and 12 224 were found to be cancer type-specific, in which cluster 4 was mainly enriched with ovarian

225 cancer samples, cluster 8 was primarily consisting of cfDNA profiles from lung cancer patients, 226 cluster 10 was GIST-specific and cluster 13 was mainly composed of colorectal samples (Fig. 227 **4**, **B**). Cluster 2, adjacent to clusters 4 and 8, was enriched with ovarian samples, although it 228 co-localized with other tumors. Clusters 9 (mostly ovarian cancer) and 15 (intermixed cancer 229 types) deviated from healthy and other malignant clusters. Majority of the cfDNA profiles from 230 breast cancer patients resembled profiles from healthy controls, while one advanced stage 231 breast cancer sample was found in cluster 8, and 2 samples from patients with advanced stage 232 primary metastatic disease were found in cluster 2 (Fig. 4, A and B).

233

234 Compared with the hematological cancer dataset, ctDNA levels estimated by ichorCNA were 235 generally lower in the solid malignant cohort (Fig. 4, C). Tumor fraction varied among 236 different types of cancer and increased with the stage (Supplemental Fig. 9). The malignant cases with detectable CNAs and therefore higher TF were more likely to separate from the 237 238 healthy controls (Supplemental Fig. 10). Cluster 4 contained ovarian cancer samples with 239 detectable chromosome instability. Among lung cancer profiles in cluster 8, 64.29% (9 out of 240 14) had detectable CNAs. Clusters 16 to 19 included four ovarian samples with high 241 chromosomal instability that greatly deviated from other profiles. Overall, in clusters 9 and 15, 242 profiles tended to be noisy, without clear CNAs (Fig. 4, D), however they deviated from 243 healthy control and other malignant clusters (Fig. 4, A). When using the log2 copy ratio profiles 244 from the CNA analysis to investigate whether the sub-grouping of cfDNA profiles was driven 245 by CNAs, cancer type-specific clustering patterns were diminished (Supplemental Fig. 11). When restricting the clustering analysis to samples with TF lower than 3%, samples from 246 247 clusters 9 and 15 still showed deviations (Fig. 4, A clusters 8 and 9) from normal profiles (Supplemental Fig. 12). 248

249

250 We next investigated whether supervised learning using genome-wide features can enhance 251 the detection of solid malignancy signals in sWGS cfDNA data. Classification of samples as 252 either healthy or malignant (107 healthy controls and 320 malignancies) was performed using 253 the SVM model, with performance estimated by LOO and repeated 10-fold CV. With an 254 overall accuracy of 65.34%, we correctly detected 177 out of 320 cancer profiles (55.31% 255 sensitivity, 95% CI: 49.68% - 60.84%), at a specificity of 95%. Performance in individual 256 tumor types ranged from 15.22% (95% CI: 6.34% - 28.87%) for classifying breast cancer to 257 80.00% (95% CI: 63.06% - 91.56%) for GIST (Supplemental Table 3). Stage of the disease 258 affected the detection, with a sensitivity of 26.17% (95% CI: 18.15% - 35.55%) in the early 259 stage (I-II) versus 69.95% (95% CI: 63.31% - 76.03%) in the advanced stage (III-IV). In 260 individual tumor types, it remained true that higher sensitivities were found for the advanced 261 stages than for the early-stage diseases (Fig. 5, A). Colorectal cancer was an exception as 262 sensitivities were almost the same for early and advanced cancer stages. Misclassified 263 malignant samples had low tumor fraction, which potentially restricted the detection of 264 underlying tumor-specific patterns (**Supplemental Fig. 13**). We could distinguish malignancy 265 from healthy samples with an AUC of 0.827 (95% CI: 0.787 - 0.867), which again was superior to ichorCNA TF-based analysis (0.733 AUC, 95% CI: 0.687 - 0.780; Fig. 5, B and 266 Supplemental Fig. 14). Subsequently, we explored the potential of our GIPX*plore* method for 267 268 tumor classification. When performing tumor type-specific prediction with the 171 correctly 269 predicted primary tumor samples, the LOO validation resulted in a 69.01% (95% CI: 61.49% 270 - 75.84%) overall accuracy. Highest sensitivities (>70%) were obtained for cfDNA samples 271 from ovarian cancer and GIST patients. At the same time, ovarian and colorectal tumor cfDNA 272 profiles were more likely to be misassigned to each other (Fig. 5, C and Supplemental Table 273 **4**).

274

275 Moreover, among this solid malignant cohort, we had nine cfDNA samples from patients with 276 ovarian metastases, of which four patients had gastrointestinal primary site, one lymphoma, 277 one leiomyosarcoma, one uterine origin, and the remaining two had Krukenberg tumors. 278 Annotation of these nine cases on the tSNE plot showed that metastatic profiles could resemble 279 profiles of either the primary tumor or the distant site (Supplemental Fig. 15, A). Applying 280 the type-specific classifier to the six metastatic cases that were predicted as malignant cases by 281 the malignancy classifier, the case with gastrointestinal origin that was co-clustered with 282 colorectal samples was classified to be colorectal class. Two out of three metastatic cases that 283 were identified in intermixed clusters of lung and ovarian tumors were predicted to be lung 284 class and the other one was assigned to ovarian class. The additional two cases identified by 285 the classifier were classified to the ovarian and colorectal classes, respectively (Supplemental 286 Fig. 15, B).

287

Accurate classification of benign from invasive and borderline adnexal masses may improve clinical management

290 In addition to the invasive ovarian tumor samples, our cohort contained 160 benign and 63 291 borderline ovarian samples. To assess the potential utility of the method for ovarian cancer 292 management, we analyzed the ovarian tumor cohort independently by performing clustering 293 analysis and building the ovarian-specific classifier to differentiate benign from malignant 294 adnexal masses. Benign and borderline samples were less likely to have detectable ctDNA 295 levels (Supplemental Fig. 16). In the clustering analysis, 35 invasive samples formed a distinct 296 group in cluster 1. In clusters 6-9, common patterns were found for invasive, benign and 297 borderline samples, although they remained distinct from controls (Supplemental Fig. 17). 298 The classification analysis exhibited an AUC of 0.8656 (95% CI: 0.7761 - 0.8689) in 299 discriminating benign from invasive samples, and an AUC of 0.7388 (95% CI: 0.6857 -

- 300 0.7920) in discriminating benign from borderline and invasive samples (**Supplemental Fig. 18**
- 301 and **19**).

302 **DISCUSSION**

We present a generic approach for cancer identification and classification by mapping genomewide cfDNA signatures, without prior knowledge of genetic alterations or predefined signatures in the sequencing data. The unsupervised clustering allows the discovery of hidden genome-wide patterns, and the supervised learning model can be trained to detect such underlying signatures. This method can be used to classify cfDNA samples by matching to existing datasets and has the potential to be used as a pan-cancer assay for detection and typing of multiple cancers from one blood draw.

310

311 Current sWGS cfDNA analyses mainly focus on the detection of somatic CNAs (17–19). These 312 methods are blind to events that involve copy neutral abnormalities. Our approach also differs 313 from the previous method that classified tumor types based on selected CNAs, and in which 314 normal-like profiles were incapable of tumor classification (20). We demonstrate that even 315 profiles without detectable CNAs carry informative and discriminative patterns in sWGS data. 316 Different recent studies have utilized methylation, transcription factor binding, fragment 317 lengths, or cfChIP-seq for cancer detection (4,12,21–25). While these studies have important 318 implications and show cfDNA as a promising biomarker, they require more specific workup 319 and/or deeper sequencing. In contrast, analysis of sWGS data can be easily adapted in clinical 320 settings and complement CNA analysis. By mapping differences among the cfDNA profiles, 321 shared abnormality patterns are captured.

322

To date, Liu *et al.* have reported the largest population-level cfDNA methylation study for multi-cancer detection, in which the targeted methylation analysis of cfDNA enabled detection of more than 50 cancer types at a sensitivity of 54.9% and at a specificity of 99% (21). This test was refined and validated in an independent follow-up study, with an overall sensitivity of

327 51.5% at 99.5% specificity was reported (26). In line with these findings, we estimate the 328 combined sensitivity of 68.03% at above 95% specificity for the hematological and solid cancer 329 cohorts. Performance for cancer signal detection varied among the different cancer types and 330 stages. The prediction accuracy was highest for hematological malignancies and lowest for 331 breast cancer. Shedding of the ctDNA from breast cancer is known to be low (27.28). Also, 332 our cohort had an over-representation of early-stage cancers, with 50% of the samples from 333 stage I. Apart from potential screening applications, we also demonstrated that GIPXplore 334 could be used for risk stratification and management of a specific cancer type. Discrimination 335 between malignant, borderline and benign masses at diagnosis is of critical importance to 336 improve patient management (29,30).

337

338 The accuracy of tumor type-specific prediction might depend on the intrinsic tumor 339 characteristics. For example, DLBCL being more heterogeneous on molecular level (31,32), 340 had lower classification accuracy than HL and MM. The subtype of colorectal and ovarian 341 tumors is of similar cellular origin, and histological subtypes can be hard to distinguish (33-342 35), which might be a reason for misclassification amongst the two cancer types. The 343 identification of the origin of some metastases, suggests the method may allow the identification of unknown primary cancers. The metastatic cases were classified into profiles 344 345 of its primary or distant sites, possibly reflecting changes during the metastatic progression or 346 dynamic tumor DNA shedding from tumor tissues (36–38).

347

Interestingly, besides tumor type- or aberration-specific subgroups, our analysis revealed the presence of additional clusters that segregated from healthy controls (**Fig. 4, B** and **Supplemental Fig. 17**). Though the origin of such segregations remains unknown, we hypothesize the method provides a system-wide insight, potentially reflecting

17

(patho)physiological conditions of these individuals. Dynamic cellular responses and malignant cell proliferation with active involvement of immune response during (early) carcinogenesis might lead to the observed common changes in cfDNA composition across different cancer types (39,40). Therefore, it is possible that our analysis detected tumor-driven immune or other biological responses or states.

357

358 GIPXplore provides an unbiased genome-wide scan of cfDNA profiles. However, it also has 359 some limitations. Increasing the sequencing depth might improve detection of disease-specific 360 cfDNA patterns and improve the sensitivity of our methodology further. The data presented 361 here has a larger proportion of HL and ovarian cancer samples and is limited in the number of 362 different cancer types, which may affect the aggregated sensitivity and distort tumor typing 363 accuracies. We foresee that expanding the breadth of the evaluated cancer types may improve 364 prediction of tissue/cell origin and facilitate a deeper understanding of cfDNA in the context 365 of tumors. Increasing the range of physiological states and diseases that are relevant for these 366 tumor samples will be essential to fully interrogate the potential and limitations of our 367 approach. The approach may also be further broadened to project and embed new treatment or 368 follow-up data for cancer prognosis and monitoring.

369

In summary, we have extended the scope of cfDNA analysis, allowing cost-effective identification of genome-wide cancer-(type-)specific signatures from shallow sequencing data, allowing improved discrimination between profiles from cancer patients and healthy individuals. This study lays the foundation for enhanced genomic characterization of cfDNA that can be used for improved cancer management. We foresee that the method can be scaled up for detection of multiple pathological conditions.

18

- Acknowledgements: We would like to acknowledge the patients and blood donors. We would
 like to thank Gitte Thirion and Annick Van den Broeck for the collection of samples and the
- 378 extraction of ctDNA, Kate Stanley for helpful suggestions for the manuscript.
- **Funding:** This study was supported by the Research Foundation-Flanders (FWO-Vlaanderen)
- 380 (G080217N to FA and JRV, G0A1116N to PV), Agentschap Innoveren en Ondernemen
- 381 (VLAIO; Flanders Innovation & Entrepreneurship grant HBC.2018.2108 to JRV), Kom Op
- 382 Tegen Kanker (Stand Up to Cancer, the Flemish Cancer Society under grant 2016/10728/2603
- to AC), Stichting tegen Kanker (FAF-C/2016/836 to PV, 2018-134 to JRV and FA) and KU
- 384 Leuven funding (no C1/018 to JRV and DL).
- 385 Conflict of interest: Patent application pending on 'Method for analyzing cell-free nucleic386 acids' (JRV and LD).
- 387 Author contributions: HC, TJ, LL, LD, FA and JRV conceptualized and designed the study.
- 388 KP, AW, EW, AC, PN, ST, DT, PV, HW and FA provided clinical samples and patient data.
- 389 LL, LV, NB, IP, KVDB, CD, DF, RH, SH, CL, L.Liekens, VP, ACT, AV and AW carried out
- 390 clinical sample procurement and processing. LV, NB, IP and KVDB coordinated sequencing
- 391 of cell-free DNA. TJ and LL conducted project coordination and administration. HC and LD
- 392 performed bioinformatics analysis of sWGS data. HC, TJ, LL, LD, KP, AW, EW, AC, DL, ST,
- 393 DT, PV, FA and JRV contributed to the interpretation of results. HC, TJ and JRV wrote the
- 394 manuscript; all co-authors reviewed the manuscript.
- 395 Data and materials availability: Processed alignments of sequencing data are archived to
 396 ArrayExpress (https://www.ebi.ac.uk/arrayexpress/) with unrestricted access under accession
 397 number E-MTAB-10934. Code will be available upon request. All other materials associated
- 398 with this study are present in the paper or the Supplementary Materials.

All rights reserved. No reuse allowed without permission.

399 **Reference**

400 1. Vandenberghe P, Wlodarska I, Tousseyn T, Dehaspe L, Dierickx D, Verheecke M, et al. 401 Non-invasive detection of genomic imbalances in Hodgkin/Reed-Sternberg cells in 402 early and advanced stage Hodgkin's lymphoma by sequencing of circulating cell-free 403 DNA: a technical proof-of-principle study. Lancet Haematol. 2015;2:e55-65. 404 2. Lenaerts L, Che H, Brison N, Neofytou M, Jatsenko T, Lefrère H, et al. Breast Cancer 405 Detection and Treatment Monitoring Using a Noninvasive Prenatal Testing Platform: 406 Utility in Pregnant and Nonpregnant Populations. Clin Chem. 2020;66:1414-23. 407 3. Lenaerts L, Vandenberghe P, Brison N, Che H, Neofytou M, Verheecke M, et al. 408 Genomewide copy number alteration screening of circulating plasma DNA: potential 409 for the detection of incipient tumors. Ann Oncol. 2019;30:85-95. 410 4. Cristiano S, Leal A, Phallen J, Fiksel J, Adleff V, Bruhm DC, et al. Genome-wide cell-free 411 DNA fragmentation in patients with cancer. Nature. Nature Publishing Group; 412 2019;570:385-9. 413 5. Lo YMD, Han DSC, Jiang P, Chiu RWK. Epigenetics, fragmentomics, and topology of 414 cell-free DNA in liquid biopsies. Science. American Association for the Advancement 415 of Science; 2021;372. Available from: 416 http://science.sciencemag.org/content/372/6538/eaaw3616 417 6. Jiang P, Sun K, Tong YK, Cheng SH, Cheng THT, Heung MMS, et al. Preferred end 418 coordinates and somatic variants as signatures of circulating tumor DNA associated 419 with hepatocellular carcinoma. Proc Natl Acad Sci. National Academy of Sciences; 420 2018;115:E10925-33. 421 7. Chan KCA, Jiang P, Sun K, Cheng YKY, Tong YK, Cheng SH, et al. Second generation 422 noninvasive fetal genome analysis reveals de novo mutations, single-base parental 423 inheritance, and preferred DNA ends. Proc Natl Acad Sci U S A. 2016;113:E8159-68. 424 8. Mouliere F, Robert B, Peyrotte EA, Rio MD, Ychou M, Molina F, et al. High 425 Fragmentation Characterizes Tumour-Derived Circulating DNA. PLOS ONE. Public 426 Library of Science; 2011;6:e23418. 427 9. Snyder MW, Kircher M, Hill AJ, Daza RM, Shendure J. Cell-free DNA Comprises an In 428 Vivo Nucleosome Footprint that Informs Its Tissues-Of-Origin. Cell. 2016;164:57-68. 429 10. Jiang P, Lo YMD. The Long and Short of Circulating Cell-Free DNA and the Ins and 430 Outs of Molecular Diagnostics. Trends Genet. Elsevier; 2016;32:360-71. 431 11. Jiang P, Chan CWM, Chan KCA, Cheng SH, Wong J, Wong VW-S, et al. Lengthening 432 and shortening of plasma DNA in hepatocellular carcinoma patients. Proc Natl Acad 433 Sci. National Academy of Sciences; 2015;112:E1317-25. 434 12. Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. 435 Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl 436 Med. American Association for the Advancement of Science; 2018;10. Available from: 437 https://stm.sciencemag.org/content/10/466/eaat4921

- 438 13. Buedts L, Wlodarska I, Finalet-Ferreiro J, Gheysens O, Dehaspe L, Tousseyn T, et al.
 439 The landscape of copy number variations in classical Hodgkin lymphoma: a joint KU
 440 Leuven and LYSA study on cell-free DNA. Blood Adv. 2021;5:1991–2002.
- 441 14. Bayindir B, Dehaspe L, Brison N, Brady P, Ardui S, Kammoun M, et al. Noninvasive
 442 prenatal testing using a novel analysis pipeline to screen for all autosomal fetal
 443 aneuploidies improves pregnancy management. Eur J Hum Genet. 2015;23:1286–93.
- 444 15. Maaten L van der, Hinton G. Visualizing Data using t-SNE. J Mach Learn Res.
 445 2008;9:2579–605.
- 446 16. Pons P, Latapy M. Computing Communities in Large Networks Using Random Walks.
 447 In: Yolum pInar, Güngör T, Gürgen F, Özturan C, editors. Comput Inf Sci ISCIS
 448 2005. Berlin, Heidelberg: Springer; 2005. page 284–93.
- 449 17. Adalsteinsson VA, Ha G, Freeman SS, Choudhury AD, Stover DG, Parsons HA, et al.
 450 Scalable whole-exome sequencing of cell-free DNA reveals high concordance with
 451 metastatic tumors. Nat Commun. Nature Publishing Group; 2017;8:1324.
- 452 18. Leary RJ, Sausen M, Kinde I, Papadopoulos N, Carpten JD, Craig D, et al. Detection of
 453 Chromosomal Alterations in the Circulation of Cancer Patients with Whole-Genome
 454 Sequencing. Sci Transl Med. American Association for the Advancement of Science;
 455 2012;4:162ra154-162ra154.
- 456 19. Ulz P, Belic J, Graf R, Auer M, Lafer I, Fischereder K, et al. Whole-genome plasma
 457 sequencing reveals focal amplifications as a driving force in metastatic prostate cancer.
 458 Nat Commun. 2016;7:12008.
- 459 20. Molparia B, Nichani E, Torkamani A. Assessment of circulating copy number variant
 460 detection for cancer screening. PLOS ONE. Public Library of Science;
 461 2017;12:e0180647.
- 462 21. Liu MC, Oxnard GR, Klein EA, Swanton C, Seiden MV, Liu MC, et al. Sensitive and
 463 specific multi-cancer detection and localization using methylation signatures in cell-free
 464 DNA. Ann Oncol. 2020;31:745–59.
- 465 22. Sun K, Jiang P, Chan KCA, Wong J, Cheng YKY, Liang RHS, et al. Plasma DNA tissue
 466 mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and
 467 transplantation assessments. Proc Natl Acad Sci. 2015;112:E5503–12.
- 468 23. Ulz P, Perakis S, Zhou Q, Moser T, Belic J, Lazzeri I, et al. Inference of transcription
 469 factor binding from cell-free DNA enables tumor subtype prediction and early
 470 detection. Nat Commun. Nature Publishing Group; 2019;10:4666.
- 471 24. Moss J, Magenheim J, Neiman D, Zemmour H, Loyfer N, Korach A, et al.
 472 Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free
 473 DNA in health and disease. Nat Commun. Nature Publishing Group; 2018;9:5068.
- 474 25. Sadeh R, Sharkia I, Fialkoff G, Rahat A, Gutin J, Chappleboim A, et al. ChIP-seq of
 475 plasma cell-free nucleosomes identifies gene expression programs of the cells of origin.
 476 Nat Biotechnol. Nature Publishing Group; 2021;1–13.

perpetuity.										
	All rights reserved.	No reuse	allowed	without permission.						

477 478 479 480	26. Klein EA, Richards D, Cohn A, Tummala M, Lapham R, Cosgrove D, et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol. Elsevier; 2021;0. Available from: https://www.annalsofoncology.org/article/S0923-7534(21)02046-9/abstract
481	27. Wan JCM, Heider K, Gale D, Murphy S, Fisher E, Mouliere F, et al. ctDNA monitoring
482	using patient-specific sequencing and integration of variant reads. Sci Transl Med.
483	American Association for the Advancement of Science; 2020;12. Available from:
484	http://stm.sciencemag.org/content/12/548/eaaz8084
485	 Moss J, Zick A, Grinshpun A, Carmon E, Maoz M, Ochana BL, et al. Circulating breast-
486	derived DNA allows universal detection and monitoring of localized breast cancer. Ann
487	Oncol. Elsevier; 2020;31:395–403.
488 489 490 491	29. Vanderstichele A, Busschaert P, Smeets D, Landolfo C, Nieuwenhuysen EV, Leunen K, et al. Chromosomal Instability in Cell-Free DNA as a Highly Specific Biomarker for Detection of Ovarian Cancer in Women with Adnexal Masses. Clin Cancer Res. American Association for Cancer Research; 2017;23:2223–31.
492	 Kaijser J. Towards an evidence-based approach for diagnosis and management of adnexal
493	masses: findings of the International Ovarian Tumour Analysis (IOTA) studies. Facts
494	Views Vis ObGyn. 2015;7:42–59.
495	31. Cascione L, Aresu L, Baudis M, Bertoni F. DNA Copy Number Changes in Diffuse
496	Large B Cell Lymphomas. Front Oncol. Frontiers; 2020;10. Available from:
497	https://www.frontiersin.org/articles/10.3389/fonc.2020.584095/full
498	 Zhang J, Grubor V, Love CL, Banerjee A, Richards KL, Mieczkowski PA, et al. Genetic
499	heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci. 2013;110:1398–
500	403.
501	 Kelemen LE, Köbel M. Mucinous carcinomas of the ovary and colorectum: different
502	organ, same dilemma. Lancet Oncol. 2011;12:1071–80.
503	34. Cheasley D, Wakefield MJ, Ryland GL, Allan PE, Alsop K, Amarasinghe KC, et al. The
504	molecular origin and taxonomy of mucinous ovarian carcinoma. Nat Commun. Nature
505	Publishing Group; 2019;10:3935.
506	35. Nishizuka S, Chen S-T, Gwadry FG, Alexander J, Major SM, Scherf U, et al. Diagnostic
507	Markers That Distinguish Colon and Ovarian Adenocarcinomas. Cancer Res.
508	2003;63:5243–50.
509	36. Wyatt AW, Annala M, Aggarwal R, Beja K, Feng F, Youngren J, et al. Concordance of
510	Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.
511	JNCI J Natl Cancer Inst. 2017;109. Available from: https://doi.org/10.1093/jnci/djx118
512	37. Wei T, Zhang J, Li J, Chen Q, Zhi X, Tao W, et al. Genome-wide profiling of circulating
513	tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver
514	metastasis. Mol Oncol. 2020;14:1966–77.

- 515 38. Cresswell GD, Nichol D, Spiteri I, Tari H, Zapata L, Heide T, et al. Mapping the breast
 516 cancer metastatic cascade onto ctDNA using genetic and epigenetic clonal tracking. Nat
 517 Commun. Nature Publishing Group; 2020;11:1446.
- 39. Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al.
 Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. Nature
 Publishing Group; 2017;545:446–51.
- 40. Kustanovich A, Schwartz R, Peretz T, Grinshpun A. Life and death of circulating cellfree DNA. Cancer Biol Ther. Taylor & Francis; 2019;20:1057–67.

523

		Stage*	Age, Mean ± SD	Female, n (%)	Total Sample
Hematological cancer dataset					
	Healthy		69 (±3)	164 (63%)	260
	Hodgkin's lymphoma (HL)		32 (±14)	98 (55%)	179
		Ι			10
		II			145
		III IV			9 15
	Diffuse large B-cell lymphoma (DLBCL)		59 (±13)	22 (60%)	37
	lymphonia (DLDCL)	Ι			1
		II			5
		III			7
		IV			8
	Multinla	unknown			16
	Multiple myeloma (MM)		67 (±9)	8 (36%)	22
		I			3
		II			7
		III unknown			7 5
Solid tume dataset	Dr				
	Healthy		49 (±12)	107 (91%)	107
	Breast	-	56 (±12)	46 (100%)	46
		I			23
		II III			12 5
		IV			6
	Colorectal	1,	66 (±12)	29 (41%)	70
		Ι			19
		II			17
		III IV			25 9
	Gastrointestinal		64 (±11)	N.A.	35
	stromal tumor (GIST)	Advanced			35
	Lung	2 Su valiccu			<u> </u>
		Advanced	N.A.	N.A.	44
	Ovarian invasive tumors		61 (±14)	125 (100%)	125
		I			25
		II			11
		III			49
					21
		IV			31 9
	Ovarian Benign		49 (±16)	160 (100%)	31 9 160

Table 1. Participant and characteristics 524

525 * Multiple myeloma stratification refers to Revised International Staging System.

526 Figure Captions

527 Fig. 1. Schematic illustration of GIPXplore. Plasma cfDNA in healthy individuals (blue box) 528 comprises short nucleosome-protected DNA fragments mainly released from the cells of 529 hematopoietic origin. In patients with cancer (green box), cfDNA is also released from the 530 tumor. Since cfDNA fragmentation pattern is cell- or tissue-specific, sequencing and mapping 531 of cfDNA from a patient with cancer may have differential genome-wide distribution of DNA 532 fragments along the genome compared to a healthy one (green and blue profiles respectively). 533 The workflow of GIPXplore combines two tasks. First, explorative analysis of the high-534 dimensional data is performed via unsupervised clustering. Data complexity is reduced by 535 using the first 50 linearly transformed genome-wide coverage features (non-trivial principal 536 components, PCs) from a large number of cfDNA profiles, which are used for dataset 537 exploration to unveil the potential biological signals or technical confounding factors based on 538 the sub-grouping of underlying patterns that facilitate the design of the supervised models. 539 Concurrently, classifiers are constructed to predict disease status and identify disease type to 540 assess the use of such transformed genome-wide features as a marker for diagnostic 541 application.

542

Fig. 2. Genome-wide cfDNA profiles carry cancer type-specific patterns. A, Two-543 544 dimensional tSNE visualization of the clustering result. Sample type is annotated by point color 545 and community detection resulted clusters are annotated by point shape. Cluster numbers are 546 labeled in the center of the defined cluster. **B**, Sample distribution in each community detection defined cluster is shown. The upper bar plot shows the total number of samples grouped in 547 548 each cluster and the lower bar plot depicts the proportion of each class of samples. C, Tumor 549 fraction estimated using ichorCNA. Red horizontal line indicates a detection limit of 3% tumor 550 fraction level. **D**, Examples of copy number profiles generated from ichorCNA for selected

551 clusters. In each copy number profile, color red represents copy number gains and green 552 represents copy number losses. The color is supposed to be interpreted together with the log 553 ratio values to pinpoint copy number gains or losses.

554

Fig. 3. Plasma cfDNA genome-wide signatures enable hematological malignancies 555 556 detection and subtype prediction. A, Sensitivities for detection of subtypes of hematological 557 malignancies. Performance for early and advanced stages for DLBCL and HL are shown. Three 558 (R-ISS) stages of MM are shown. 95% confidence interval is shown as an error bar. B, ROC 559 curves for performance comparison between the genome-wide feature analysis and ichorCNA 560 tumor fraction analysis. For the genome-wide feature analysis, decision value from SVM 561 prediction is used to build a dynamic threshold of true and false positives. Tumor fraction 562 values were used to construct ROC for ichorCNA analysis. C, Confusion matrix for tissue of 563 origin detection in hematological tumor. The color shading represents the proportion of 564 samples being correctly localized. The labeled numbers indicate the number of samples being 565 classified into the class.


566

567 Fig. 4. Clustering analysis elucidates profile representations in solid tumors. A, Two-568 dimensional tSNE visualization of solid tumor dataset clustering result. Sample type is 569 annotated by point color and community detection resulted clusters are annotated by point 570 shape. Cluster numbers are labeled in the center of the defined cluster. **B**, Sample distribution 571 in each community detection defined cluster is shown. The upper bar plot shows the total number of samples grouped in each cluster and the lower bar plot depicts the proportion of 572 573 each class of samples. C, Tumor fraction estimation for indicated types of solid tumors. Red 574 horizontal line indicates a detection limit of 3% tumor fraction level. **D**, Examples of copy 575 number profiles generated from ichorCNA for selected clusters.

576

Fig. 5. Malignancy detection and typing in solid tumors. A, Sensitivities for detection of 577 578 different types of solid malignancies detection. Performance for detection of early and 579 advanced stages of disease is shown. **B**, ROC curves for performance comparison between the 580 genome-wide feature analysis and ichorCNA tumor fraction analysis. C, Confusion matrix for 581 tissue of origin detection in solid malignancies. The color shading represents the proportion of 582 samples being correctly localized. The labeled numbers indicate the number of samples being 583 classified into the class.

Figure 1.









Figure 3.







A

B

С




Figure 5.

A

B

С

